A Bacteriophage T4 Nanoparticle-Based Dual Vaccine against Anthrax and Plague

Pan Tao,a Marthandan Mahalingam,a Jingen Zhu,a Mahtab Moayeri,b Jian Sha,c,d William S. Lawrence,c,d Stephen H. Leppla,b Ashok K. Chopra,c,d,e,f,g Venigalla B. Raoa

aDepartment of Biology, The Catholic University of America, Washington, DC, USA
bMicrobial Pathogenesis Section, Laboratory of Parasitic Diseases, NIAID, NIH, Bethesda, Maryland, USA
cDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, USA
dGalveston National Laboratory, University of Texas Medical Branch, Galveston, Texas, USA
eInstitute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, Texas, USA
fSealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas, USA
gCenter for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, Texas, USA

ABSTRACT Bacillus anthracis and Yersinia pestis, the causative agents of anthrax and plague, respectively, are two of the deadliest pathogenic bacteria that have been used as biological warfare agents. Although Biothrax is a licensed vaccine against anthrax, no Food and Drug Administration-approved vaccine exists for plague. Here, we report the development of a dual anthrax-plague nanoparticle vaccine employing bacteriophage (phage) T4 as a platform. Using an in vitro assembly system, the 120- by 86-nm heads (capsids) of phage T4 were arrayed with anthrax and plague antigens fused to the small outer capsid protein Soc (9 kDa). The antigens included the anthrax protective antigen (PA) (83 kDa) and the mutated (mut) capsule antigen F1 and the low-calcium-response V antigen of the type 3 secretion system from Y. pestis (F1mutV) (56 kDa). These viral nanoparticles elicited robust anthrax- and plague-specific immune responses and provided complete protection against inhalational anthrax and/or pneumonic plague in three animal challenge models, namely, mice, rats, and rabbits. Protection was demonstrated even when the animals were simultaneously challenged with lethal doses of both anthrax lethal toxin and Y. pestis CO92 bacteria. Unlike the traditional subunit vaccines, the phage T4 vaccine uses a highly stable nanoparticle scaffold, provides multivalency, requires no adjuvant, and elicits broad T-helper 1 and 2 immune responses that are essential for complete clearance of bacteria during infection. Therefore, phage T4 is a unique nanoparticle platform to formulate multivalent vaccines against high-risk pathogens for national preparedness against potential bioterror attacks and emerging infections.

IMPORTANCE Following the deadly anthrax attacks of 2001, the Centers for Disease Control and Prevention (CDC) determined that Bacillus anthracis and Yersinia pestis that cause anthrax and plague, respectively, are two Tier 1 select agents that pose the greatest threat to the national security of the United States. Both cause rapid death, in 3 to 6 days, of exposed individuals. We engineered a virus nanoparticle vaccine using bacteriophage T4 by incorporating key antigens of both B. anthracis and Y. pestis into one formulation. Two doses of this vaccine provided complete protection against both inhalational anthrax and pneumonic plague in animal models. This dual anthrax-plague vaccine is a strong candidate for stockpiling against a potential bioterror attack involving either one or both of these biothreat agents. Further, our results establish the T4 nanoparticle as a novel platform to develop multivalent vaccines against pathogens of high public health significance.
Vaccines are one of the most successful medical interventions of the past millennium (1). Millions of lives have been saved by mass administration of vaccines against deadly pathogens such as smallpox and flu. However, effective vaccines are still lacking for many pathogens, including biothreat agents such as the Gram-positive bacterium *Bacillus anthracis* that causes anthrax and the Gram-negative bacterium *Yersinia pestis* that causes plague. According to the Centers for Disease Control and Prevention (CDC), these two organisms are two of the Tier 1 select agents that pose the greatest threat to national security (2). Both are highly virulent resulting in mortality (as high as 100%) of the subjects within 3 to 6 days of infection. The organisms can be weaponized and transmitted through inhalation of aerosolized droplets and can be disseminated relatively easily for the purposes of biological warfare or bioterrorism (3, 4). Designing a vaccine that can protect the public against these threats is therefore a national priority. Additionally, plague is a significant threat to global health. It causes periodic outbreaks around the world. The latest example is the 2017 Madagascar outbreak that resulted in 209 deaths (>70% of the cases were pneumonic plague) (5).

Vaccine development historically relied on the whole pathogen containing either the inactivated (heat- or formalin-killed) organisms or live attenuated (less virulent mutant) organisms (1). Several such vaccines have been developed against anthrax and plague in the past. The Biothrax anthrax vaccine (AVA [anthrax vaccine alum-adsorbed]) is derived from the culture filtrate of the attenuated *B. anthracis* strain V770-NP1-R (6, 7). This strain secretes the anthrax protective antigen (PA), a primary target for anthrax vaccine design, into the culture medium, but also traces of the other two components of the tripartite anthrax toxin, the lethal factor (LF) and the edema factor (EF) (6–8). This vaccine does have untoward side effects, and therefore, new anthrax vaccines are highly sought. Similarly, plague vaccines were developed using the formalin-killed or live attenuated *Yersinia pestis* bacteria (9–11). However, these whole-pathogen vaccines produce severe side effects such as reactogenicity at the injection site. Hence, these vaccines have either been discontinued or used only in a limited way to protect at-risk military and laboratory personnel (6, 10–12).

Subunit vaccines containing only the target antigen(s) of a pathogen are safer alternatives to whole-pathogen vaccines (13, 14). Numerous recombinant vaccines against anthrax or plague have been under investigation, but none have yet been licensed (6, 15–18). The recombinant anthrax vaccines are composed primarily of PA (6, 18), whereas the plague vaccines contain two surface antigens of *Y. pestis*, the capsular protein Caf1 (or F1) (15.6 kDa) and the low-calcium-response V antigen LcrV (or V) (37.2 kDa) (15–17). A bivalent vaccine consisting of all three antigens fused into a single polypeptide has also been developed (19). However, the subunit vaccines generally are unstable, may not generate sufficient immune responses for complete protection, and require the addition of nonspecific “adjuvants” such as aluminum hydroxide or liposomes to enhance immunogenicity and protective efficacy (13, 20–22).

One of the reasons for poor immunogenicity of subunit vaccines is the lack of the pathogen-associated molecular patterns (PAMPs) observed in whole-pathogen vaccines, which are recognized by the host immune system and trigger innate as well as adaptive immune responses (22, 23). One way to overcome this limitation is to incorporate the target antigen as part of a virus nanoparticle structure (24–27). Phages, such as T4, lambda, and M13, have been used as viral nanoparticle platforms to display antigens (28–30). The antigen molecules so arrayed on the nanoparticle surface would mimic the PAMPs of a pathogenic virus, potentially leading to stimulation of strong immune responses (24, 25).

Here, we report the development of a dual viral nanoparticle vaccine against both anthrax and plague using bacteriophage (phage) T4 (Fig. 1). The 120- by 86-nm-size phage T4 head (capsid) is decorated with anthrax PA (83 kDa) and plague F1mutV.
(56 kDa) fused to the small outer capsid protein (Soc) (9 kDa). F1mutV is a fusion protein of a mutant F1 antigen and V antigen. The mutant F1 produces a soluble monomeric protein, as opposed to the native F1 which polymerizes into heterogeneous aggregates, yet it retains the full immunogenicity of the native protein (17). Since Soc assembles on phage T4 capsid as a trimer at the quasi-three-fold axes (Fig. 1A) (31, 32), the PA and F1mutV antigens attached to Soc might be recognized by the host immune system as repeating structures arranged symmetrically on the nanoparticle (Fig. 1B), similar to PAMPs. Indeed, our studies demonstrated that such nanoparticles generated robust antigen-specific immune responses and provided complete protection against both anthrax and plague in three different animal models, namely, mice, rats, and rabbits. Furthermore, the T4 nanoparticle vaccine, unlike the traditional subunit vaccines, do not require any adjuvant and generated balanced Th1- and Th2-based antibody responses, which are highly desirable for any vaccine but particularly relevant for clearance of pathogenic plague bacteria (10, 33). Finally, the T4 nanoparticle vaccine provided complete protection against simultaneous challenge by both anthrax lethal toxin (LeTx) and Y. pestis CO92. These results suggest that the phage T4 vaccine might be a good candidate for stockpiling against a potential bioterror attack involving either one or both of these biothreat agents. Further, our results establish the T4 nanoparticle as a novel platform to develop multivalent biodefense vaccines containing additional biothreat antigens, as well as for engineering vaccines against other emerging pathogens of high public health significance.

RESULTS

Preparation of T4 nanoparticles decorated with anthrax and plague antigens. To develop a phage T4 vaccine against both B. anthracis and Y. pestis, we constructed three recombinants by fusing the anthrax and plague antigens to phage RB69 Soc. The three recombinants were F1mutV-Soc-PA (148 kDa), F1mutV-Soc (66 kDa), and Soc-PA (93 kDa). Our previous studies have shown that both the N and C termini of RB69 Soc are exposed on the capsid surface, and both can be used to display recombinant proteins efficiently (34, 35). Phage RB69 is closely related to T4, and its Soc protein binds to phage T4 capsid as well as the T4 Soc protein does (34). As reported previously (34), the binding affinity, copy number per capsid, and capsid stabilization by Soc binding are nearly the same for RB69 Soc as those of T4 Soc. However, we observed that proteins fused to RB69 Soc showed greater solubility than the proteins fused to T4 Soc (17). Since such solubility is a significant factor in vaccine manufacture, we used RB69 Soc instead of T4 Soc for antigen display. The choice of the plague antigen F1mutV and the anthrax antigen PA was based on our previous studies in which these antigens stimulated protective immune responses in animal models (17, 19, 36-38). The Histagged recombinant proteins were overexpressed in Escherichia coli and purified by immobilized nickel affinity chromatography followed by size exclusion chromatography (see Fig. S1 in the supplemental material). The purified proteins were then
assembled on T4 nanoparticles in three different display formats: (i) display of F1mutV-Soc-PA, (ii) display of F1mutV-Soc and Soc-PA on the same capsid, and (iii) a 1:1 mixture of T4 phage particles separately displayed with F1mutV-Soc or Soc-PA. Of these display formats, the latter produced particles with the highest copy number of antigens per capsid, whereas F1mutV-Soc-PA produced the lowest copy number. Hence, this formulation, a mixture of T4 nanoparticles displaying either F1mutV-Soc or Soc-PA (abbreviated as T4-F1mutV/PA) was selected for immunological studies.

To optimize the copy number for immunization experiments, 2 x 10¹⁰ particles of purified Soc− (and Hoc−) phage were incubated with F1mutV-Soc or Soc-PA proteins at different ratios of antigen molecules to Soc binding sites (Fig. 1B and 2). Binding increased with increasing ratio, reaching saturation at ~20:1 (Fig. 2). The copy numbers of antigens displayed per capsid (B_max) were 650 for the 66-kDa F1mutV-Soc and 361 for the 93-kDa Soc-PA, and the binding concentrations at which half of the capsid binding sites were occupied (BC50) were 348 nM and 1,140 nM, respectively (Fig. 2; see Materials and Methods for details on the determination of B_max and BC50). Since there are 870 Soc binding sites per capsid, the percent occupancy values were 75 for F1mutV-Soc and 41 for Soc-PA. These values represent high occupancies, considering that both the 83-kDa PA and the 56-kDa F1mutV would encounter steric constraints to access all the Soc binding sites on the capsid surface, the former more so than the latter, as reflected in the data.

The T4 nanoparticles decorated with anthrax and plague antigens provide near-complete protection to mice against anthrax lethal toxin and pneumonic plague challenges with *Y. pestis* CO92. BALB/c mice (10 mice per group) were immunized by the intramuscular (i.m.) route with 25 μg of each of the T4 nanoparticle preparations containing F1mutV-Soc and Soc-PA and boosted on day 21 (Fig. 3A). Mice
immunized with the T4 phage lacking the antigens served as a control group. A series of experiments were performed to determine the immunogenicity and protective efficacy of the T4-delivered antigens. Enzyme-linked immunosorbent assays (ELISAs) showed high levels of both F1V-specific and PA-specific IgG antibodies, up to endpoint titers of $10^6$ (Fig. 3B). Anthrax lethal toxin (LeTx) neutralization assays demonstrated that the T4-PA immunized animals also elicited robust LeTx neutralization titers (the dilution of serum inducing 50% neutralization [EC50] of 4,052) (Fig. 3C). The control animals were negative for both types of antibodies (Fig. 3B and C).

The protective efficacy of T4-delivered F1mutV/PA was evaluated by two dual-challenge models that we have recently developed: (i) sequential challenge (Fig. 3D) in which the animals were first exposed to one threat agent and the survivors were then exposed to the second threat agent, and (ii) simultaneous challenge (Fig. 3E) in which the animals were exposed to both threat agents at the same time. For sequential challenge, mice (10 mice per group) immunized as described above (Fig. 3A) were injected intraperitoneally (i.p.) with one 100% lethal dose (LD100) of LeTx (1:1 mixture of PA and LF [100 µg each]) on day 42. The immunized group was 80% protected against LeTx challenge, whereas 100% of the negative-control mice died within 2 days of challenge (Fig. 3D). Thirty-three days later, the surviving animals were challenged with 400 50% lethal doses (LD50) of Y. pestis CO92 by intranasal (i.n.) administration to develop pneumonic plague. The naive mice were used as negative controls. The T4-F1mutV/PA group showed 100% protection (no death), whereas the naive animals showed 100% death within 4 days after Y. pestis CO92 challenge (Fig. 3D).

For simultaneous dual challenge, mice ($n = 8$) immunized by the same scheme (Fig. 3A) were challenged with both LeTx (1 LD100, i.p. administration) and Y. pestis CO92 (200 LD50, i.n. administration) 23 days after the boost (Fig. 3A). As shown in Fig. 3E, all the control mice died within 2 days of challenge, whereas the T4-delivered F1mutV/PA provided 88% protection (one death out of eight mice). Furthermore, the survivors showed clearing of Y. pestis bacteria by 3 days postchallenge (Fig. 3F). The Y. pestis CO92 strain used in the challenge experiment contained a luciferase (lux) expression cassette for imaging the bacteria in vivo in real time (39). The immunized animals were
negative for bioluminescence, whereas the control mice showed bacterial dissemination throughout the body (Fig. 3F); these data were confirmed by colony count determination at the termination of the experiment or as the animals succumbed to infection (data not shown).

The T4 nanoparticles provide complete protection to rats against both anthrax and plague. The rat is a natural host for *Y. pestis* infection, which occurs through rat fleas. Therefore, rats are one of the most reliable models to assess the protective efficacy of vaccines against plague (40). Likewise, rats are exquisitely sensitive to LeTx (19). To evaluate the immunogenicity and protective efficacy of the T4 bivalent vaccine using this model, Brown Norway rats (*n* = 9) were immunized using the scheme shown in Fig. 4A. The T4-delivered immunogens induced high levels of antigen-specific IgG titers in rats, up to $1.25 \times 10^5$ and $6.25 \times 10^5$ of F1mutV-specific and PA-specific IgG, respectively (Fig. 4B). The T4-F1mutV/PA group consistently also generated high levels of LeTx neutralizing antibodies (EC$_{50}$ of 4,285 ± 409) (Fig. 4C). The control animals, as expected, were negative for the antigen-specific total IgG and LeTx neutralizing antibodies (Fig. 4B and C).

The protective efficacy of the T4 bivalent vaccine in rats was also tested by our dual-challenge models (Fig. 4D and E). For sequential challenge, the animals (*n* = 9) were first subjected to i.n. challenge with 400 LD$_{50}$ of *Y. pestis* CO92. The T4 bivalent vaccine showed 100% protection, whereas all the rats in the control group died within 2 days postchallenge (Fig. 4D). The surviving rats were then challenged with 1 LD$_{100}$ of LeTx (7.5 µg each of PA and LF) by intravenous (i.v.) injection on day 70 after *Y. pestis* CO92 challenge. All the rats immunized with T4 dual anthrax-plague vaccines survived (Fig. 4D), but rats in the control group (negative control) died within 2 h of the LeTx challenge. This is consistent with previous studies in that rats are highly sensitive to i.v. administration of LeTx, a challenge regime that results in rapid death (19). In a separate experiment, the protective efficacy of the T4 vaccine was further evaluated by the simultaneous dual-challenge model where the rats (*n* = 6) were immunized as de-
scribed above and challenged with both LeTx (1 LD\textsubscript{100}, i.v.) and \textit{Y. pestis} CO92 (400 LD\textsubscript{50}, i.n.) at the same time (Fig. 4E). The T4 dual vaccines once again showed 100% protection, whereas the control animals succumbed to either the LeTx challenge or to \textit{Y. pestis} infection (Fig. 4E).

The T4 nanoparticle vaccine induces high levels of both T\textsubscript{H1}- and T\textsubscript{H2}-dependent antibody responses. Stimulation of both arms of the immune system, humoral (T\textsubscript{H2}) and cellular (T\textsubscript{H1}), is essential for protection against \textit{Y. pestis} infection (10), and probably beneficial for protection against \textit{B. anthracis} infection (41). With this in mind, we determined the IgG subclass of the induced antibodies (Fig. 5). In mice, the IgG2a titer represents the T\textsubscript{H1} response, whereas the IgG1 titer reflects the T\textsubscript{H2} response. Our data showed that the T4-displayed F1mutV/PA group elicited high levels of both IgG1 and IgG2a antibodies against F1mutV or PA, whereas the control animals were negative for both types of antibodies (Fig. 5A and B). The IgG subclass specificity of the antibodies induced in rats exhibited trends similar to those in mice (Fig. 5C and D). The T4 nanoparticle-displayed F1mutV/PA induced high levels of both IgG1 and IgG2a antibodies against both F1mutV and PA immunogens (Fig. 5C and D). However, a bias toward T\textsubscript{H1} was even stronger in the case of anti-PA than in the case of anti-F1mutV (Fig. 5C and D). These results, which were consistently observed in two animal models, showed that the T4 nanoparticle-delivered antigens stimulated strong antibody responses derived from both the T\textsubscript{H1} cellular system and the T\textsubscript{H2} humoral system (17, 42). In contrast, we and others have previously noted that soluble antigens (with Alhydrogel as an adjuvant) showed a clear bias toward the T\textsubscript{H2} responses (17, 43). This is also consistent with the clearance of pathogenic \textit{Y. pestis lux} bacteria in the challenge experiments described above. However, more studies are needed to directly examine the T\textsubscript{H1} and T\textsubscript{H2} responses and to further explore the mechanisms of T4 nanoparticle vaccine-induced protection.

The T4 nanoparticles confer complete protection to rabbits against inhalational anthrax. The T4 dual anthrax-plague vaccine was further evaluated in a New Zealand White (NZW) rabbit model that is considered to be the best model for inhalation anthrax. The pathology of rabbits challenged with aerosolized Ames spores shows remarkable similarity to that in humans infected with encapsulated toxigenic \textit{B. anthracis} spores (44, 45). NZW rabbits (10 rabbits per group) were primed on day 0 and boosted on day 14 by the i.m. injection of the T4 bivalent anthrax-plague vaccine formation (Fig. 6A). Sera were collected on the schedule shown in Fig. 6A and subjected to immunological analyses. The data showed that the T4 nanoparticle vaccines induced
high levels of anti-PA IgG antibodies as well as LeTx neutralizing antibodies on day 20 (Fig. 6B and C). The rabbits also induced high levels of anti-F1mutV antibodies, up to an endpoint titer of $1.6 \times 10^6$ (Fig. 6D). The control group showed no antibodies to either PA or F1mutV (Fig. 6B to D).

Rabbits were challenged 2 weeks after the boost with 200 LD$_{50}$ of aerosolized B. anthracis Ames spores. All the naive control rabbits succumbed to the anthrax disease 2 to 4 days postinfection, while the T4 dual-vaccine-immunized rabbits were 100% protected (Fig. 6E). Blood samples for bacteremia were drawn before the challenge on day 27 and on days 29 to 33 (2 to 6 days postexposure) and 42 (15 days postexposure). Bacteremia was not detected in vaccinated animals, whereas all unvaccinated animals became positive for bacteremia before they succumbed to the disease. To determine the bacterial loads of internal organs, postmortem collection of specimens was performed after scheduled euthanasia of surviving animals on study day 42 (T4-F1mutV/PA group) or after animals died due to the anthrax exposure (control group). All vaccinated animals had cleared the agent from the lungs and did not have any bacteria in the brain, liver, or spleen. In contrast, tissue samples collected from control animals were positive for B. anthracis (except for one rabbit whose liver was negative), indicating systemic anthrax infection.

**DISCUSSION**

The deadly anthrax attacks of 2001 using weaponized spores of B. anthracis illustrated the enormous dangers posed by biothreat agents in creating chaos and terror among the public (3, 4). Stockpiling of a biodefense vaccine that can protect people against multiple biothreat agents would provide an effective countermeasure to mitigate such future attacks. Despite intense efforts for nearly 2 decades, no such vaccine is on the horizon for licensure. We describe here a nanoparticle vaccine delivery platform using phage T4 that can be engineered to create multivalent biodefense vaccines against different pathogens. As a proof of principle, a dual anthrax-plague vaccine is formulated by incorporating three different antigens from two Tier 1 select agents into phage T4 nanoparticles; protective antigen from B. anthracis and the capsular protein F1 and the low-calcium-response V antigen from Y. pestis.
The anthrax and plague antigens were assembled in vitro on the capsid of phage T4 through fusion to the phage outer capsid protein Soc. High-affinity interactions between Soc and the capsid fixed the antigens at symmetric positions of the capsid lattice. Recent studies showed that repeat structures of the viral capsid could be recognized by Toll-like receptor 2 (TLR-2) as a PAMP and could lead to the induction of an innate immune response (46). Therefore, a simple mixture of anthrax and plague antigen particles, with the displayed antigens resembling the repeat structures or molecular patterns seen on a natural viral pathogen, might then be presented to the host immune system.

Strikingly, the T4 nanoparticle vaccine elicited high titers of antigen-specific antibodies against both anthrax and plague antigens. Neither antigenic interference nor enhancement of antibody responses was evident. Furthermore, the dual vaccine was highly efficacious in protecting animals against lethal challenges with anthrax and/or plague agent. This was observed in three different animal models: BALB/c mice, Brown Norway rats, and New Zealand White rabbits. Indeed, complete protection of vaccinated animals was observed even when the animals were simultaneously challenged with LeTx and the highly virulent Y. pestis CO92 bacteria in the rat model or in an inhalational anthrax model where the rabbits were challenged with the aerosolized Ames spores of B. anthracis. These models represent two of the best models available to assess the efficacy of plague and anthrax vaccines, respectively.

It is significant that the dual anthrax-plague vaccine, unlike the traditional subunit vaccines, elicited robust immune responses against both antigens in the absence of an adjuvant. In fact, addition of adjuvants such as Alhydrogel and/or liposomes to the nanoparticles did not enhance the immune responses (data not shown). We speculate that this might be because the viral nanoparticles, mimicking the PAMPs of a natural pathogen, engage with the TLRs and robustly stimulate the innate and adaptive immune systems of the host and do not need an external adjuvant (46). Consistent with this hypothesis, the T4 dual vaccine elicited both Th1- and Th2-mediated antibody responses against both antigens. This seems to be a signature characteristic of the phage T4 nanoparticle platform, one that is highly desirable for clearance of pathogenic organisms during natural infection. However, further studies are needed to understand the mechanisms.

In conclusion, our studies highlight some unique properties of the T4 phage nanoparticle that are distinct from the traditional subunit vaccines, which could facilitate formulation of multivalent vaccines against high-risk pathogens. Potentially, additional antigens from other biothreat agents and/or from emerging pathogens could be incorporated using the same principle, and these formulations can be customized to address different threats in different geographical regions of the world. Additional advantages of phage T4 platform include the following: highly stable structure, scalability, cost-effectiveness, safety, and lack of preexisting immunity in humans. Together, these factors could accelerate the streamlining of clinical trials, manufacture, and deployment at a much reduced cost, time, and effort. Phage T4, thus, is a good candidate to develop as a “universal” platform for creating and stockpiling multivalent vaccines as part of our national preparedness against potential future biothreats and emerging infections. With some more refinement, this platform may have the most desirable target product profile for licensure.

MATERIALS AND METHODS

Ethics statement. This study was conducted in accordance with the Guide for the Care and Use of Laboratory Animals (47) recommended by the National Institutes of Health. All animal experiments were performed according to the protocols approved by the Institutional Animal Care and Use Committees of the University of Texas Medical Branch, Galveston, TX (Office of Laboratory Animal Welfare assurance number A3314-01), The Catholic University of America, Washington, DC (Office of Laboratory Animal Welfare assurance number A4431-01), and Southern Research Institute, Birmingham, AL (Office of Laboratory Animal Welfare assurance number A3046-01). All of the select agent animal research was conducted in the animal biosafety level 3 (ABSL3) suite, and the principal investigators have registered with the CDC to work with these pathogens.
Plasmids, bacterial, and phage T4. The E. coli expression vector pET28b (EMD Biosciences, Darmstadt, Germany) was used for recombinant plasmid construction. Expression plasmid pET-F1mutV/Soc was constructed previously (17, 48). The pET-Soc-PA plasmid was constructed by replacing the F1mutV gene of pET-F1mutV-PA (19) with Soc, which was amplified from pET-F1mutV/Soc by PCR. The amplified Soc fragment was doubly digested with Nhel and HindIII and cloned into pET-F1mutV-PA, linearized with the same enzymes, to replace F1mutV. The resulting pET-Soc-PA contains the Soc gene fused in frame to the N terminus of PA with a short linker (Glu-Ala-Ser-Ala) between the Soc gene and PA. All plasmids were confirmed by sequencing. E. coli strains DH5α were used for cloning. E. coli strain P301 was used to propagate hoc soc phage T4 as described previously (49–51). The E. coli BL21-CodonPlus (DE3)-RIPL cells (Agilent Technologies, Santa Clara, CA) were used for expression of genes encoding target proteins.

Purification of proteins. The E. coli BL21-CodonPlus (DE3)-RIPL cells containing either pET-Soc-PA or pET-F1mutV/Soc were induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 2 to 3 h at 28°C. Recombinant proteins were purified as described previously (17, 48). Briefly, cells were harvested and resuspended in binding buffer (50 mM Tris-HCl [pH 8], 300 mM NaCl, and 20 mM imidazole) containing protease inhibitor cocktail (Roche, USA, Indianapolis, IN). After the cells were lysed at 19,610 lb/in² using a French press (Aminco, Urbana, IL), the soluble fractions of cell lysates containing the His-tagged fusion proteins were isolated by centrifugation. Proteins were purified first by HisTrap column (AKTA-priime; GE Healthcare Bio-Sciences Corp., Piscataway, NJ) followed by size exclusion chromatography on a HiLoad 16/60 Superdex 200 column (AKTA-FPLC; GE Healthcare). The proteins were then quantified and stored at −80°C until use.

Purification of Hoc soc T4 phage. Hoc soc T4 phages were purified as described previously (48, 49). Briefly, the propagated T4 phage on E. coli P301 was collected by centrifugation for 45 min at 25,000 × g. The supernatant containing T4 phages was resuspended in 0.5 M MgCl₂ buffer (26 mM Na₂HPO₄, 68 mM NaCl, 22 mM KH₂PO₄, 1 mM MgSO₄ [pH 7.5]) containing 10 μg/ml DNase I and chloroform (0.4 ml) and incubated at 37°C for 30 min. The lysate was subjected to low-speed centrifugation (6,000 × g for 10 min) and high-speed centrifugation (35,000 × g for 45 min), and the final phage pellet was resuspended in 200 μl of Tris-Mg buffer (10 mM Tris-HCl [pH 7.5], 50 mM NaCl, and 5 mM MgCl₂) and purified by CsCl density gradient centrifugation.

In vitro binding of antigens to phage T4. In vitro binding of Soc fusion proteins to Hoc soc T4 phage was conducted as previously described (17, 48). The same batch of purified phages was used for all the animal immunization experiments (below). The proteins and phages used were highly pure, after going through multiple rounds of purification steps as described above. As previously reported (17), the endotoxin levels in three different batches of purified proteins ranged from 0.05 to 0.8 endotoxin unit (EU) per ml, well below the maximum recommended endotoxin levels, 10 and 20 EU/ml, in gene vectors going through multiple rounds of purification steps as described above. As previously reported (17), the endotoxin levels in three different batches of purified proteins ranged from 0.05 to 0.8 endotoxin unit (EU) per ml, well below the maximum recommended endotoxin levels, 10 and 20 EU/ml, in gene vectors going through multiple rounds of purification steps as described above.

Mouse immunizations and challenges. Six- to eight-week-old female BALB/c mice (17 to 20 g) purchased from The Jackson Laboratory (Bar Harbor, ME) were randomly assigned to groups and allowed to acclimate for 7 days. Antigens were displayed on T4 as described above. A total of 50 μg antigen (25 μg of each F1mutV and PA) was injected on days 0 and 21 via the i.m. route. Control mice received the same amount of T4 but without any antigen. Blood samples were collected from each animal by the retro-orbital route on day 0 (prebleeds) and day 35 for immunological analyses. Mice were sequentially or simultaneously challenged with LeTx and Y. pestis CO92 as described previously (19). Briefly, in sequential challenge, mice were ip. challenged first with 1 LD₅₀ of LeTx, followed by i.n. challenge with 400 LD₅₀ (1 LD₅₀ = 100 CFU in BALB/c mice) of Y. pestis CO92 33 days after LeTx challenge. In a separate...
simultaneous challenge experiment, mice were immunized as described above and ip. challenged with 1 LD$_{100}$ of LeTx, followed by i.n. challenge with 200 LD$_{50}$ Y. pestis CO92 on the same day. All animals were anesthetized by inhalation of 2% to 4% isoflurane (to effect) before challenge. Animals were monitored twice daily for mortality and other clinical symptoms.

**Rat immunizations and challenges.** Female Brown Norway rats (50 to 75 g) were purchased from Charles River Laboratories (New Jersey) and randomly grouped. After 7 days acclimation, rats were immunized by intramuscular (i.m.) route with T4-displayed antigens prepared as described above. Twenty-five micrograms of each antigen was used for immunizations as indicated in the figures. The animals were bled on day 35 by the saphenous vein, and sera were obtained for immunological analyses. Rats were sequentially challenged on day 42 with ~400 LD$_{50}$ Y. pestis CO92 (i.n.) followed by 1 LD$_{100}$ LeTx (7.5 μg of each of the toxin components [LF and PA]) challenge (i.v.). In a separate simultaneous challenge experiment, rats (six rats per group) were immunized as described above and challenged simultaneously with 1 LD$_{100}$ of LeTx and 400 LD$_{50}$ Y. pestis CO92 3 weeks after boost. All rats were anesthetized by inhalation of 2% to 4% isoflurane (to effect) before challenge. Rats were monitored twice a day for morbidity and mortality.

**Rabbit immunization and challenge.** The rabbit study was conducted by the Southern Research Institute (study number 13538.01.15; Birmingham, AL). A total of 16 New Zealand White rabbits were randomly divided into two groups. Group 1 was vaccinated with T4-displayed antigen (50 μg) (10 rabbits, equal numbers of males and females), while group 2 received the same amount of T4 but without any antigen (6 rabbits, equal numbers of males and females). Rabbits were immunized on days 0 and 14. Sera were collected on days 0 (preimmune), 12, 20, and 42 for immunological analyses. For the challenge experiment, the animals were loaded in the head-out plethysmograph, and a custom designed nose-only inhalation challenge mask was placed over the snout of each rabbit so that the mouth and nares were covered. At the start of the challenge period, the nebulizer and liquid impinger were actuated. Animals received the aerosol challenge until a cumulative inhaled volume of 20 liters had been reached. The inhalation exposure time was 11.7 to 22.8 min. Animals were challenged with 200 LD$_{50}$ of aerosolized B. anthracis Ames spores on day 28 and monitored for morbidity and mortality until day 42. The remaining animals were then euthanized by an intravenous administration of a barbiturate overdose, and tissues (brain, liver, lung, and spleen) were collected for B. anthracis detection on the same day. Blood samples (approximately 0.2 ml) were also collected on days 27, 29 to 33, and 42 for microbiological analysis (bacteriemia).

**Determination of IgG and IgG subtype antibodies.** Antibody titers were determined by ELISA as described previously (17, 42). Briefly, each well of a 96-well plate was coated with 100 ng of F1mutV or PA diluted in coating buffer (0.05 M sodium carbonate-sodium bicarbonate [pH 9.6]) overnight at 4°C. The plates were then blocked with 3% bovine serum albumin (BSA) in PBS (pH 7.4) for 1 h at 37°C. After 1 h of incubation at 37°C with serially diluted serum samples, plates were washed with PBS-T (PBS with 0.1% Tween 20 [pH 7.4]). For total IgG, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (KPL, Gaithersburg, MD), rabbit anti-rat IgG (Invitrogen), or goat anti-rabbit IgG (KPL, Gaithersburg, MD) was used as the secondary antibody. For mouse or rat IgG subtypes, HRP-conjugated goat anti-mouse or HRP-conjugated mouse anti-rat IgG1 or IgG2a secondary antibodies (Abcam, Cambridge, MA) were used. Samples were initially diluted 1:200; serial fivefold dilutions were performed as necessary to ensure that values reached the endpoint. For rabbit anti-PA IgG titers, plates were coated with PA, and affinity-purified rabbit anti-PA polyclonal antibody was used to generate a standard curve, from which the sample anti-PA IgG concentrations (in nanograms per milliliter) were determined. 3,3′,5,5′-Tetramethylbenzidine (TMB) microwell peroxidase substrate kit (KPL, Gaithersburg, MD) was used for staining.

**Anthrax LeTx neutralization assay.** Anthrax lethal-toxin-neutralizing assay was performed as described previously (53). Briefly, PA and LF were diluted to the final concentration of 200 ng/ml with Dulbecco’s modified Eagle’s medium (DMEM). Serially diluted serum samples were added to the toxin mixture, incubated for 1 h at 37°C, and then transferred to RAW264.7 macrophage cells grown to confluence in 96-well plates and incubated for 5 h. The viability of cells was assessed by incubation with MTT (3-(4,5-dimethylthiazolo-2-yI)-2,5-diphenyltetrazolium bromide) (Sigma, St. Louis, MO) at a final concentration of 0.5 mg/ml for 30 min. The medium was aspirated, the insoluble pigment (formazan) produced by living cells was dissolved by adding a solution containing 0.5% SDS, 25 mM HCl, and 90% isopropanol, and the optical density (570 nm) was measured to assess viability. The effective serum concentration inducing 50% neutralization (EC$_{50}$) was calculated with Graphpad Prism-7 software (San Diego, CA).

**Live-animal imaging.** In vivo imaging was performed as described previously (39). Briefly, 3 days after challenge with Y. pestis CO92-luciferase strain, the animals were imaged by using an IVIS 200 bioluminescence and fluorescence whole-body imaging workstation (Caliper Corp., Alameda, CA) in the ABSL-3 at the University of Texas Medical Branch (UTMB) facility after lightly anesthetizing the animals with isoflurane.

**Statistical analyses.** Results are expressed as means ± standard deviations (SD). Statistical comparisons between groups were evaluated by Student’s t test. The animal mortality data were analyzed by the Kaplan-Meier survival estimate. A P value of <0.05 was considered statistically significant.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at https://doi.org/10.1128/mBio.01926-18.

FIG S1, TIF file, 2 MB.
ACKNOWLEDGMENTS

We thank Victor Padilla-Sanchez (The Catholic University of America) for assistance with Figure 1, Ayca Akal-Strader (The Catholic University of America) for critically reviewing and editing the manuscript, Lanling Zou (NIAID, NIH) for discussions, Raymond M. Slay (NIAD, NIH) for coordinating the rabbit study, and Jonathan Rayner (Southern Research Institute, Birmingham, AL, USA) for the rabbit study.

This work was supported by NIAID/NIH grant AI111538 (V.B.R.) and in part by grant AI064389 (A.K.C.) and the intramural research program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health.

REFERENCES

1. Rappuoli R, Pizza M, Del Giudice G, De Gregorio E. 2014. Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A 111:12288–12293. https://doi.org/10.1073/pnas.1402981111.

2. Centers for Disease Control and Prevention. 2017. Bioterrorism agents/diseases. Centers for Disease Control and Prevention, Atlanta, GA. https://emergency.cdc.gov/agent/agentlist-category.asp. Accessed 17 August 2017.

3. Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Gerberding JL, Redd SC, Nottingham JH, Wholey M, Hancock WR, Osterholm MT, Hickam DH, Brame W, Delfino R, Goldstein H, Perl TM, Sarber DM, Stover SL, Uyeki TM. 2004. Anthrax as a biologic weapon—medical and public health management. Working Group on Civilian Biodefense. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236–2252. https://doi.org/10.1001/jama.287.17.2236.

4. Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Fine AD, Friedlander AM, Hauer J, Kuofer J, Layton M, McCade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Socol-Spana M, Tonat K. 2000. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 283:2281–2290. https://doi.org/10.1001/jama.283.17.2281.

5. World Health Organization - Regional Office for Africa. 2017. Plague outbreak Madagascar. External situation report 14. World Health Organization - Regional Office for Africa, Cité du Djoué, Republic of Congo.

6. Leppla SH, Robbins JB, Schneerson R, Shiloach J. 2002. Development of a rationally designed anthrax vaccine. J Clin Invest 110:141–144. https://doi.org/10.1172/JCI10216204.

7. Williamson ED, Dyson EH. 2015. Anthrax prophylaxis: recent advances and future directions. Front Microbiol 6:1009. https://doi.org/10.3389/fmicb.2015.01009.

8. Santelli E, Bankston LA, Leppla SH, Liddington RC. 2004. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 430:905–908. https://doi.org/10.1038/nature02763.

9. Rosenzweig JA, Jejelowo O, Sha J, Erova TE, Brackman SM, Kirtley ML, van Lier CJ, Chopra AK. 2011. Progress on plague vaccine development. Appl Microbiol Biotechnol 91:265–286. https://doi.org/10.1007/s00253-011-3380-6.

10. Smiley ST. 2008. Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 7:209–221. https://doi.org/10.1586/14760584.7.2.209.

11. Sun W, Curtiss R. 2013. Rational considerations about development of live attenuated Yersinia pestis vaccines. Curr Pharm Biotechnol 14:878–886.

12. McCombs RC, Marchenko M. 2016. Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen—the first step toward a rationally designed anthrax vaccine. Vaccine 34:13–19. https://doi.org/10.1016/j.vaccine.2015.11.025.

13. Karch CP, Burkhard P. 2016. Vaccine technologies: from whole organisms to rationally designed protein assemblies. Biochem Pharmacol 120:1–14. https://doi.org/10.1016/j.bcp.2016.05.001.

14. Schiller JT, Lowry DR. 2015. Raising expectations for subunit vaccine. J Infect Dis 211:1373–1375. https://doi.org/10.1093/infdis/jiu648.

15. Williamson ED, Eley SM, Griffin KF, Green M, Russell P, Leary SE, Oyston PC, Easterbrook T, Reddin KM, Robinson A, Tittball RW. 1995. A new tk2improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12:223–230. https://doi.org/10.1111/j.1574-695X.1995.tb00196.x.

16. Heath DG, Anderson GW, Jr, Mauro JM, Welkos SL, Andrews GP, Ad- amovicz J, Friedlander AM. 1998. Protection against experimental bubby and pneumatic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 16:1131–1137. https://doi.org/10.1016/S0264-410X(98)80110-2.

17. Tao P, Mahalingam M, Kirtley ML, van Lier CJ, Sha J, Yeager LA, Chopra AK, Rao VB. 2013. Mutated and bacteriophage T4 nanoparticle arrayed F1-V immunogens from Yersinia pestis as next generation plague vaccine. PLoS Pathog 9:e1003495. https://doi.org/10.1371/journal.ppat.1003495.

18. Kaur M, Singh S, Bhatnagar R. 2013. Anthrax vaccines: present status and future prospects. Expert Rev Vaccines 12:955–970. https://doi.org/10.1586/14760584.2013.814860.

19. Tao P, Mahalingam M, Zhu J, Moayeri M, Kirtley ML, Fitsc EC, Andersen JA, Lawrence WS, Leppla SH, Chopra AK, Rao VB. 2017. A bivalent anthrax-plague vaccine that can protect against two Tier-I bioterror pathogens, Bacillus anthracis and Yersinia pestis. Front Immunol 8:687. https://doi.org/10.3389/fimmu.2017.00687.

20. O’Souza AJ, Man KD, Huang J, Majumdar S, Ford BM, Dyas B, Ulrich RG, Sullivan VJ. 2013. Rapid deamidation of recombinant protective antigen when adsorbed on aluminum hydroxide gel correlates with reduced potency of vaccine. J Pharm Sci 102:454–461. https://doi.org/10.1002/jps.23422.

21. Wagner L, Verma A, Meade BD, Reiter K, Narum DL, Brady RA, Little SF, Burns DL. 2012. Structural and immunological analysis of anthrax recombiant protective antigen adsorbed to aluminum hydroxide adjuvant. Clin Vaccine Immunol 19:1465–1473. https://doi.org/10.1128/CVI.01714-12.

22. Coffman RL, Sher A, Seder RA. 2010. Vaccine adjuvants: putting innate immunity to work. Immunity 33:492–503. https://doi.org/10.1016/j.immuni.2010.09.002.

23. Leititz SM, Golenbock DT. 2012. Beyond empiricism: informing vaccine development through innate immunity research. Cell 148:1284–1292. https://doi.org/10.1016/j.cell.2012.02.012.

24. Örfr E, Szebeni J. 2016. The immune system of the gut and potential adverse effects of oral nanocarriers on its function. Adv Drug Deliv Rev 106:402–409. https://doi.org/10.1016/j.addr.2016.09.009.

25. Jain NK, Sahni N, Kumru OS, Joshi SB, Volkin DB, Russell Middaugh C. 2013. Formulation and stabilization of recombinant protein based virus-like particle vaccines. Adv Drug Deliv Rev 65:43–54. https://doi.org/10.1016/j.addr.2013.10.015.

26. Roldao A, Mellado MC, Castillo LR, Carrondo MJ, Alves PM. 2010. Virus-like particles in vaccine development. Expert Rev Vaccines 10:1149–1176. https://doi.org/10.1586/erv.10.115.

27. Tao P, Luo M, Zhu D, Qu S, Yang Z, Gao M, Guo D, Pan Z. 2009. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol 22:273–281. https://doi.org/10.1089/vim.2009.0017.

28. Chang JR, Song EH, Nakatani-Webster E, Monkkonen L, Ratner DM, Catalano CE. 2014. Phage lambda capsids as tunable display nanoparticles. Biomacromolecules 15:4410–4419. https://doi.org/10.1021/bm501164c.

29. Tao P, Zhu J, Mahalingam M, Batra H, Rao VB. 2018. Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases. Adv Drug Deliv Rev

30. Prisco A, De Berardinis P. 2012. Filamentous bacteriophage fd as an improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med Microbiol 12:223–230. https://doi.org/10.1111/j.1574-695X.1995.tb00196.x.
A T4 Nanoparticle-Based Anthrax-Plague Vaccine

isometric head at 3.3-A resolution and its relevance to the assembly of icosahedral viruses. Proc Natl Acad Sci U S A 114:EB184–EB193. https://doi.org/10.1073/pnas.1708483114.

32. Fokine A, Chipman PR, Leiman PG, Mesyanzhinov VV, Rao VB, Rossmann MG. 2004. Molecular architecture of the prolate head of bacteriophage T4. Proc Natl Acad Sci U S A 101:6003–6008. https://doi.org/10.1073/pnas.0400444101.

33. Parent MA, Berggren KN, Kummer LW, Wilhelm LB, Szaba FM, Mullarky EM, Smiley ST. 2005. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun 73:7304–7310. https://doi.org/10.1128/IAI.73.11.7304-7310.2005.

34. Qin L, Fokine A, O’Donnell E, Rao VB, Rossmann MG. 2010. Structure of the small outer capsid protein, Soc: a clamp for stabilizing capsids of T4-like phages. J Mol Biol 395:728–741. https://doi.org/10.1016/j.jmb.2009.10.007.

35. Li Q, Shivachandra SB, Zhang Z, Rao VB. 2007. Assembly of the small outer capsid protein, Soc, on bacteriophage T4: a novel system for high density display of multiple large anthrax toxins and foreign proteins on phage capsid. J Mol Biol 370:1006–1019. https://doi.org/10.1016/j.jmb.2007.05.008.

36. Peachman KK, Li Q, Matyas GR, Shivachandra SB, Lovchik J, Lyons RC, Alving CR, Rao VB, Rao M. 2012. Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand White rabbits against challenge with Bacillus anthracis Ames strain spores. Clin Vaccine Immunol 19:11–16. https://doi.org/10.1128/CVI.05376-11.

37. Rao M, Peachman KK, Li Q, Matyas GR, Shivachandra SB, Borschel R, Morthole VI, Fernandez-Prada C, Alving CR, Rao VB. 2011. Highly effective generic adjuvant systems for orphan or poverty-related vaccines. Vaccine 29:873–877. https://doi.org/10.1016/j.vaccine.2010.11.049.

38. Sha J, Kirtley ML, Klages C, Evora TE, Telepnev M, Ponnusamy D, Fitts EC, Baze WB, Sivasubramani SK, Lawrence WS, Patrikeev I, Peel JE, Andersson JA, Kozlova EV, Tiner BL, Peterson JW, McWilliams D, Patel S, Rothe E, Motin VL, Chopra AK. 2016. A replication-defective human type S adenovirus-based trivalent vaccine confers complete protection against plague in mice and nonhuman primates. Clin Vaccine Immunol 23:586–600. https://doi.org/10.1128/CVI.00150-16.

39. Sha J, Roszenzewig JA, Kirtley ML, van Lier CJ, Fitts EC, Kozlova EV, Evora TE, Tiner BL, Chopra AK. 2013. A non-invasive in vivo imaging system to study dissemination of bioluminescent Yersinia pestis CO92 in a mouse model of pneumonic plague. Microb Pathog 55:39–50. https://doi.org/10.1016/j.micpath.2012.09.011.

40. Agar SL, Sha J, Foltz SM, Evora TE, Walberg KG, Baze WB, Suarez G, Peterson JW, Chopra AK. 2009. Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92. Microbes Infect 11:205–214. https://doi.org/10.1016/j.micinf.2008.11.009.

41. Ovsyannikova IG, Pankratz VS, Vierkant RA, Pajewski NM, Quinn CP, Kaslow RA, Jacobson RM, Poland GA. 2013. Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed. Infect Immun 81:2584–2591. https://doi.org/10.1128/IAI.00269-13.

42. Tao P, Mahalingam M, Marasa BS, Zhang Z, Chopra AK, Rao VB. 2013. In vitro and in vivo delivery of genes and proteins using the bacteriophage T4 DNA packaging machine. Proc Natl Acad Sci U S A 110:5846–5851. https://doi.org/10.1073/pnas.1300867110.

43. Rosenthal JA, Huang CJ, Doody AM, Leung T, Mineta K, Feng DD, Wayne EC, Nishimura N, Leifer C, DeLisa MP, Mendez S, Putnam D. 2014. Mechanistic insight into the TH1-biased immune response to recombinant subunit vaccines delivered by probiotic bacteria-derived outer membrane vesicles. PLoS One 9:e112802. https://doi.org/10.1371/journal.pone.0112802.

44. Twenhafel NA. 2010. Pathology of inhalational anthrax animal models. Vet Pathol 47:819–830. https://doi.org/10.1128/VI.00958510.378112.

45. Zaucha GM, Pitt LM, Estep J, Iwins BE, Friedlander AM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch Pathol Lab Med 122:982–992.

46. Shepardson KM, Schwarz B, Larson K, Morton RV, Avera J, McCoy K, Caffrey A, Harmsen A, Douglas T, Rynda-Apple A. 2017. Induction of antiviral immune response through recognition of the repeating subunit pattern of viral capsids is Toll-like receptor 2 dependent. mBio 8:e01356-17. https://doi.org/10.1128/mbio.01356-17.

47. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.

48. Tao P, Mahalingam M, Rao VB. 2016. Highly effective soluble and bacteriophage T4 nanoparticle plague vaccines against Yersinia pestis. Methods Mol Biol 1403:499–518. https://doi.org/10.1007/978-1-4939-3387-7_28.

49. Tao P, Li Q, Shivachandra SB, Rao VB. 2017. Bacteriophage T4 as a nanoparticle platform to display and deliver pathogen antigens: construction of an effective anthrax vaccine. Methods Mol Biol 1581:255–267. https://doi.org/10.1007/978-1-4939-6869-5_15.

50. Tao P, Wu X, Tang WC, Zhu J, Rao V. 2017. Engineering of bacteriophage T4 genome using CRISPR-Cas9. ACS Synth Biol 6:1952–1961. https://doi.org/10.1021/acssynbio.7b00179.

51. Tao P, Wu X, Rao V. 2018. Unexpected evolutionary benefit to phages imparted by bacterial CRISPR-Cas9. Sci Adv 4:eaaar4134. https://doi.org/10.1126/sciadv.aar4134.

52. Brito LA, Singh M. 2011. Acceptable levels of endotoxin in vaccine formulations during preclinical research. J Pharm Sci 100:34–37. https://doi.org/10.1002/jps.22267.

53. Chen Z, Moayeri M, Zhao H, Crown D, Leppla SH, Purcell RH. 2009. Potent antiviral immuneresponse through recognition of therepeatingsubunit pattern of viral capsids is Toll-like receptor 2 dependent. mBio 8:e01356-17. https://doi.org/10.1128/mbio.01356-17.

54. Kaslow RA, Jacobson RM, Poland GA. 2013. Human leukocyte antigens and cellular immune responses to anthrax vaccine adsorbed. Infect Immun 81:2584–2591. https://doi.org/10.1128/IAI.00269-13.